Choose a language and wait for the translated text.
The government plans to address the high costs of innovative medicines by first negotiating prices. Compulsory licensing will be considered only after other alternatives are exhausted. Trade margins on high-cost drugs are being examined to enhance affordability. Discussions are ongoing with pharmaceutical companies to improve access and affordability of patented drugs. The government is also working on initiatives to support the local pharmaceutical manufacturing sector.
